MAIA Study Outcomes

obr has 860 videos Subscribe Here

Description: Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine provides outcomes from the MAIA study that compares daratumumab + lenalidomide + dexamethasone versus lenalidomide + dexamethasone in multiple myeloma elderly patients.
Shared By : obr
Posted on : 07/02/19
Added : 14 days ago
Category : Multiple Myeloma